Summit Therapeutics Inc. (SMMT)
| Previous close | 10.92 |
| Open | 9.07 |
| Bid | 8.13 x 200 |
| Ask | 8.69 x 100 |
| Day's range | 7.51 - 9.50 |
| 52-week range | 1.52 - 11.25 |
| Volume | |
| Avg. volume | 3,555,577 |
| Market cap | 6.097B |
| Beta (5Y monthly) | -1.13 |
| PE ratio (TTM) | 22.86 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate
- Business Wire
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
MIAMI, May 31, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), received marketing authorization in China from the National Medical Products Administration (NMPA). The approval is based on the positive dataset associated with HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso with data generated and analyzed by Akeso.
- Business Wire
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, May 30, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 200,000 shares of common stock. An award was made to one new employee of the Company. The award was granted as an inducement material to the new employee becoming an employee of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and has been approved by the Company’s Compensation Committee. The
